| Heading: |
Alzheimer's Disease: Drugs |
| Question ID: |
1814499 |
| UIN: |
61301 |
| House: |
Commons |
| Date tabled: |
2025-06-19 |
| Asking Member ID: |
5072 |
| Asking Member display name: |
Mr Andrew Snowden
|
| Asking Member handle: |
A_J_Snowden
|
| Asking Member Twitter reference: |
@A_J_Snowden
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, if he will publish the cost-benefit modelling for the prescription of (a) donanemab and (b) lecanemab for patients with early-stage Alzheimer’s disease. |
| Is named day: |
true |
| Date of holding answer: |
2025-06-25 |
| Date answered: |
2025-06-25 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence has published the company’s evidence submission, which includes the company’s evidence on costs and benefits, and the external assessment group report, which assesses the company’s evidence submission ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |